---
figid: PMC9670483__12951_2022_1697_Fig4_HTML
pmcid: PMC9670483
image_filename: 12951_2022_1697_Fig4_HTML.jpg
figure_link: /pmc/articles/PMC9670483/figure/Fig4/
number: Fig. 4
figure_title: ''
caption: PDA-PEG NPs regulates osteoclastogenesis-related genes and proteins. a Expression
  of osteoclast-related genes including NFATC1, TRAP, c-FOS, DC-STAMP, cathepsin K,
  and CALCR. n = 3. b Expression of NFATC1 protein assessed by western blotting. c Effects
  of PDA-PEG NPs on NF-κB pathway proteins including p-IκBα/IκBα, p‐p65/p65. d MAPK
  signaling pathway proteins including p-ERK/ERK, p-JNK/JNK, and p-p38/p38 were evaluated.
  Symbol “*” denotes p < 0.05, “**” denotes p < 0.01, NS indicates not significant
article_title: Antioxidant PDA-PEG nanoparticles alleviate early osteoarthritis by
  inhibiting osteoclastogenesis and angiogenesis in subchondral bone.
citation: Zhikai Wu, et al. J Nanobiotechnology. 2022;20:479.
year: '2022'

doi: 10.1186/s12951-022-01697-y
journal_title: Journal of Nanobiotechnology
journal_nlm_ta: J Nanobiotechnology
publisher_name: BioMed Central

keywords:
- PDA-PEG NPs
- Osteoarthritis
- Osteoclastogenesis
- Angiogenesis
- ROS
- PDGF-BB

---
